Therapy for polycystic ovarian syndrome

Current Opinion in Pharmacology

Volumn 3, Issue 6, 2003, Pages 678-682

  Wei, Alex Y ^a   Pritts, Elizabeth A ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACIPIMOX; ACTIVIN; ANDROGEN; ANDROSTENEDIONE; ANTILIPEMIC AGENT; CLOMIFENE CITRATE; CORTISONE; CYPROTERONE ACETATE; DEXAMETHASONE; EFLORNITHINE; FINASTERIDE; FLUTAMIDE; FOLLISTATIN; FOLLITROPIN; GLUCOSE; GONADOTROPIN; HYPERGLYCEMIC AGENT; INSULIN; KETOCONAZOLE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROGESTERONE; ROSIGLITAZONE; SPIRONOLACTONE; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ANDROGEN BLOOD LEVEL; ANOREXIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ENDOCRINE DISEASE; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFERTILITY; INSULIN RESISTANCE; LIVER TOXICITY; MORBIDITY; NAUSEA; OBESITY; OLIGOMENORRHEA; OVARIECTOMY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOGENESIS; PRIORITY JOURNAL; REPRODUCTION; SKIN MANIFESTATION; SYMPTOMATOLOGY; WEIGHT REDUCTION;

EID: 0344876511     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.06.004     Document Type: Review

References (52)

1. The American College of Obstetricians and Gynecologists: Polycystic ovary syndrome. ACOG Practice Bulletin December 2002, 41:1-14.
2. Zawadzki JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome. Edited by Dunaif A, Givens JR, Haselting FP, Merriam GR. Oxford, England: Blackwell Scientific; 1992:377-84.
3. Welt C.K. The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction Curr Opin Obstet Gynecol 14 2002 317-323
4. Yeh J, Adashi EY: The ovarian life cycle. In Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, edn 4. Edited by Yen SSC, Jaffe RB, Barbieri RL. Philadelphia: WB Saunders Company; 1999:159-190.
5. Franks S. Mason H. Willis D. Follicular dynamics in the polycystic ovary syndrome Mol Cell Endocrinol 163 2000 49-52
6. Eldar-Geva T. Spitz I.M. Groome N.P. Margalioth E.J. Homburg R. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome Hum Reprod 16 2001 2552-2556
7. Burghen G.A. Givens J.R. Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease J Clin Endocrinol Metab 50 1980 1130-116
8. Ehrmann D.A. Barnes R.B. Rosenfield R.L. Cavaghan M.K. Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome Diabetes Care 22 1999 141-146
9. Polonsky K. Sturis J. Bell G. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance N Engl J Med 334 1996 777-783
10. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(suppl 1):S5-S20.
11. Kahn C.R. Insulin action, diabetogenesis and the cause of type II diabetes Diabetes 43 1994 1066-1084
12. Nestler J.E. Jakubowicz D.J. de Vargas A.F. Brik C. Quintero N. Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system J Clin Endocrinol Metab 83 1998 2001-2005
13. Bergh C. Carlsson B. Olsson J.H. Selleskog U. Hillensjo T. Regulation of androgen production in cultural human thecal cells by insulin-like growth factor I and insulin Fertil Steril 59 1993 323-331
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis Endocr Rev 18 1997 774-800
15. Nestler J.E. Powers L.P. Matt D.W. Steingold K.A. Plymate S.R. Rittmaster R.S. Clore J.N. Blackard W.G. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome J Clin Endocrinol Metab 72 1992 83-89
16. Conover C.A. Lee P.K.D. Kanaley J.A. Clarkson J.T. Jensen M.D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans J Clin Endocrinol Metab 74 1992 1355-1360
17. Clark A.M. Thornley B. Tomlinson L. Galletley C. Norman R.J. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment Hum Reprod 13 1998 1502-1505
18. Kiddy D.S. Hamilton-Fairley D. Bush A. Short F. Anyaoku V. Reed M.J. Franks S. Improvement in endocrine and ovarian function during dietary tratment of obese women with polycystic ovary syndrome Clin Endocrinol 36 1992 105-111
19. Huber-Buchholz M.M. Carey D.G. Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and leuteinizing hormone J Clin Endocrinol Metab 84 1999 1470-1474
20. Pasquali R. Antenucci D. Casimirri F. Venturoli S. Paradisi R. Fabbri R. Balestra V. Melchiondra N. Barbara L. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss Clin Endocrinol Metab 68 1989 173-179
21. Guzick D.S. Wing R. Smith D. Berga S.L. Winters S.J. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women Fertil Steril 61 1994 598-604
22. Kirpichnikov D. McFarlane S.I. Sowers J.R. Metformin: an update Ann Intern Med 2137 2000 25-33
23. Moghetti P. Castello R. Negri C. Tosi F. Perrone F. Caputo M. Zanolin E. Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation J Clin Endocrinol Metab 85 2000 139-146
24. Glueck C.J. Wang P. Fontaine R. Tracy T. Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS) J Adolesc Health 29 2001 160-169
25. Nestler J.E. Stovall D. Akhter N. Iuorno M.J. Jakubowicz D.J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome Fertil Steril 77 2002 209-215
26. Moller D.E. Greene D.A. Peroxisome proliferator-activated receptor (PPAR)-γ agonists for diabetes Adv Protein Chem 56 2001 181-212
27. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome Nature 414 2001 821-827
28. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN (PCOS/Troglitazone Study Group): Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86:1626-1632.
29. Azziz R. Ehrmann D.A. Legro R.S. Fereshetian A.G. O'Keefe M. Ghazzi M.N. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome Fertil Steril 79 2003 932-937
30. Zheng Z. Li M. Lin Y. Ma Y. Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome Chung-Hua Fu Chan Ko Tsa Chih 37 2002 271-273
31. Shobokshi A. Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined resiglitazone and clomiphene citrate therapy J Soc Gynecol Investig 10 2003 99-104
32. Ghazeeri G. Kutteh W.H. Bryer-Ash M. Haas D. Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome Fertil Steril 79 2003 562-566
33. Farquhar C, Vandekerckhove P, Lilford R: Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome (Cochrane Review). In The Cochrane Library, issue 4. Oxford: Update Software; 2001 [URL: http:www.update-software.com/cochrane].
34. Parsanezhad M.E. Alborzi S. Motazedian S. Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial Fertil Steril 78 2002 1001-1004
35. Gal M. Eldar-Geva T. Margalioth E.J. Barr I. Orly J. Diamant Y.Z. Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome Fertil Steril 72 1999 26-31
36. Azziz R. The evaluation and management of hirsutism Obstet Gynecol 100 2003 1389-1402
37. Sherwin R. Quinn M.J. PCOS and OCPs? Am J Obstet Gynecol 185 2001 777-778
38. Falsetti L. Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome Acta Obstet Gynecol Scand 74 1995 56-70
39. Korytkowski M.T. Mokan M. Horwitz M.J. Berga S.L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome J Clin Endocrinol Metab 80 1995 3327-3334
40. Morin-Papunen L. Vauhkonen I. Koivunen R. Ruokonen A. Martikainen H. Tapanainen J.S. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovarian syndrome: a randomized study J Clin Endocrinol Metab 88 2003 148-156
41. Elter K. Imir G. Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study Hum Reprod 17 2002 1729-1737
42. Moghetti P. Tosi F. Tosti A. Negri C. Misciali C. Perrone F. Caputo M. Muggeo M. Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, doubld blind, placebo-controlled trial J Clin Endocrinol Metab 85 2000 89-94
43. Mercurio M.G. Hirsutism: diagnosis and management J Gend Specif Med 4 2001 29-34
44. Venturoli S. Marescalchi O. Colombo F.M. Macrelli S. Ravaioli B. Bagnoli A. Paradisi R. Flamigni C. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism J Clin Endocrinol Metab 35 1999 1304-1310
45. Armstrong V.L. Wiggam M.I. Ennis C.N. Sheridan B. Traub A.I. Atkinson A.B. Bell P.M. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate QJM 94 2001 31-37
46. Ciampelli M. Leoni F. Lattanzi F. Guido M. Apa R. Lanzone A. A pilot study of the long-term effects of acipimox in polycystic ovarian syndrome Hum Reprod 17 2002 647-653
47. Ciampelli M. Muzj G. Leoni F. Romualdi D. Belosi C. Cento R.M. Lanzone A. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome J Clin Endocrinol Metab 86 2001 5324-5329
48. Nestler J.E. Jakubowicz D.J. Reamer P. Gunn R.D. Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome N Engl J Med 340 1999 1314-1320
49. Nestler J.E.Jakubowicz D.J.Iuorno M.J.Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome J Pediatr Endocrinol Metab 13suppl 5 2000 1295-1298
50. Villa P. Valle D. Mancini A. De Marinis L. Pavone V. Fulghesu A.M. Mancuso S. Lanzone A. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism Fertil Steril 71 1999 115-121
51. Fruzzetti F. Bersi C. Parrini D. Ricci C. Genazzani A.R. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome Fertil Steril 77 2002 936-940
52. Cozzolino D. Sessa G. Salvatore T. Sasso F.C. Giuliano D. Lefebvre P.J. Torella R. The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people J Clin Endocrinol Metab 81 1996 713-718